Overview

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This research is studying the preventative use of topical 0.1% tazarotene gel daily in addition to best practice standards to reduce the development of hand-foot skin reaction (HFSR).
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Bayer
Treatments:
Nicotinic Acids
Tazarotene